POLL: Which September FDA Approval Were You Most Excited About?

Poll

Click here to answer this week's poll.

Which September FDA Approval Were You Most Excited About?

Dupilumab for prurigo nodularis
Deucravacitinib for psoriasis
DaxibotulinumtoxinA for glabellar lines
Spesolimab for generalized pustular psoriasis
Related Content

POLL: What is an Ideal Initial Treatment for Low-Risk Basal Cell Carcinoma?

September 6th 2023

POLL: What Topical Treatments Do You Find the Most Efficacious in Acne Vulgaris Management?

September 5th 2023

POLL: Do You Diagnose and Treat Psoriasis Through Telehealth Appointments?

September 1st 2023

POLL: What Treatment Approach Do You Find Most Successful for Improving Melasma?

August 28th 2023

POLL: What Type of Psoriasis Do You Most Commonly Treat in Your Practice?

August 21st 2023

POLL: Do You Encounter Patients Who Are Unaware of the Risks of Skin Lightening Products?

July 25th 2023

POLL: What is an Ideal Initial Treatment for Low-Risk Basal Cell Carcinoma?

September 6th 2023

POLL: What Topical Treatments Do You Find the Most Efficacious in Acne Vulgaris Management?

September 5th 2023

POLL: Do You Diagnose and Treat Psoriasis Through Telehealth Appointments?

September 1st 2023

POLL: What Treatment Approach Do You Find Most Successful for Improving Melasma?

August 28th 2023

POLL: What Type of Psoriasis Do You Most Commonly Treat in Your Practice?

August 21st 2023

POLL: Do You Encounter Patients Who Are Unaware of the Risks of Skin Lightening Products?

July 25th 2023

POLL: What is an Ideal Initial Treatment for Low-Risk Basal Cell Carcinoma?

September 6th 2023

POLL: What Topical Treatments Do You Find the Most Efficacious in Acne Vulgaris Management?

September 5th 2023

POLL: Do You Diagnose and Treat Psoriasis Through Telehealth Appointments?

September 1st 2023

POLL: What Treatment Approach Do You Find Most Successful for Improving Melasma?

August 28th 2023

POLL: What Type of Psoriasis Do You Most Commonly Treat in Your Practice?

August 21st 2023

POLL: Do You Encounter Patients Who Are Unaware of the Risks of Skin Lightening Products?

July 25th 2023
© 2023 MJH Life Sciences

All rights reserved.